BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 33524008)

  • 1. Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.
    Wang C; Wei X; Shao G
    Med Sci Monit; 2021 Feb; 27():e927727. PubMed ID: 33524008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma.
    Xue H; Yu Z; Liu Y; Yuan W; Yang T; You J; He X; Lee RJ; Li L; Xu C
    Int J Nanomedicine; 2017; 12():5271-5287. PubMed ID: 28769563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chitosan-g-TPGS nanoparticles for anticancer drug delivery and overcoming multidrug resistance.
    Guo Y; Chu M; Tan S; Zhao S; Liu H; Otieno BO; Yang X; Xu C; Zhang Z
    Mol Pharm; 2014 Jan; 11(1):59-70. PubMed ID: 24229050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma.
    Yang H; Ding R; Tong Z; Huang J; Shen L; Sun YU; Liao J; Yang Z; Hoffman RM; Wang C; Meng X
    Anticancer Res; 2016 Jun; 36(6):2675-82. PubMed ID: 27272776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TPGS-Galactose-Modified Polydopamine Co-delivery Nanoparticles of Nitric Oxide Donor and Doxorubicin for Targeted Chemo-Photothermal Therapy against Drug-Resistant Hepatocellular Carcinoma.
    Du Z; Mao Y; Zhang P; Hu J; Fu J; You Q; Yin J
    ACS Appl Mater Interfaces; 2021 Aug; 13(30):35518-35532. PubMed ID: 34286569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of co-treatment with doxorubicin and verapamil loaded into chitosan nanoparticles on diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Abo Mansour HE; El-Batsh MM; Badawy NS; Mehanna ET; Mesbah NM; Abo-Elmatty DM
    Hum Exp Toxicol; 2020 Nov; 39(11):1528-1544. PubMed ID: 32519553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galactose-modified selenium nanoparticles for targeted delivery of doxorubicin to hepatocellular carcinoma.
    Xia Y; Zhong J; Zhao M; Tang Y; Han N; Hua L; Xu T; Wang C; Zhu B
    Drug Deliv; 2019 Dec; 26(1):1-11. PubMed ID: 31928356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein.
    Xiang QF; Zhang DM; Wang JN; Zhang HW; Zheng ZY; Yu DC; Li YJ; Xu J; Chen YJ; Shang CZ
    Liver Int; 2015 Mar; 35(3):1010-23. PubMed ID: 24621440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surfactin-based nanoparticles loaded with doxorubicin to overcome multidrug resistance in cancers.
    Huang W; Lang Y; Hakeem A; Lei Y; Gan L; Yang X
    Int J Nanomedicine; 2018; 13():1723-1736. PubMed ID: 29606866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin.
    Wang YJ; Huang Y; Anreddy N; Zhang GN; Zhang YK; Xie M; Lin D; Yang DH; Zhang M; Chen ZS
    Oncotarget; 2016 Feb; 7(5):5877-91. PubMed ID: 26716507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-delivery of DOX and PDTC by pH-sensitive nanoparticles to overcome multidrug resistance in breast cancer.
    Cheng X; Li D; Sun M; He L; Zheng Y; Wang X; Tang R
    Colloids Surf B Biointerfaces; 2019 Sep; 181():185-197. PubMed ID: 31132609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin-loaded Fe
    Cheng C; Li C; Zhu X; Han W; Li J; Lv Y
    J Biomater Appl; 2019 May; 33(10):1373-1381. PubMed ID: 30880566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanovesicle-mediated delivery of anticancer agents effectively induced cell death and regressed intrahepatic tumors in athymic mice.
    George J; Yan IK; Patel T
    Lab Invest; 2018 Jul; 98(7):895-910. PubMed ID: 29748614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihepatoma peptide, scolopentide, derived from the centipede scolopendra subspinipes mutilans.
    Hu YX; Liu Z; Zhang Z; Deng Z; Huang Z; Feng T; Zhou QH; Mei S; Yi C; Zhou Q; Zeng PH; Pei G; Tian S; Tian XF
    World J Gastroenterol; 2023 Mar; 29(12):1875-1898. PubMed ID: 37032730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
    Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
    Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomicelles based on a boronate ester-linked diblock copolymer as the carrier of doxorubicin with enhanced cellular uptake.
    Xu Y; Lu Y; Wang L; Lu W; Huang J; Muir B; Yu J
    Colloids Surf B Biointerfaces; 2016 May; 141():318-326. PubMed ID: 26874117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma.
    Xu F; Liao JZ; Xiang GY; Zhao PX; Ye F; Zhao Q; He XX
    Cancer Med; 2017 Mar; 6(3):651-661. PubMed ID: 28135055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo.
    Barraud L; Merle P; Soma E; Lefrançois L; Guerret S; Chevallier M; Dubernet C; Couvreur P; Trépo C; Vitvitski L
    J Hepatol; 2005 May; 42(5):736-43. PubMed ID: 15826724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indocyanine green/doxorubicin-encapsulated functionalized nanoparticles for effective combination therapy against human MDR breast cancer.
    Chen HH; Lu IL; Liu TI; Tsai YC; Chiang WH; Lin SC; Chiu HC
    Colloids Surf B Biointerfaces; 2019 May; 177():294-305. PubMed ID: 30771581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.